Scopus Bio preps trials of gene-silencing immuno-oncology drugScopus BioPharma has licensed a gene-silencing drug from California’s City of Hope hospital that is due to start Share XScopus Bio preps trials of gene-silencing immuno-oncology drughttps://pharmaphorum.com/news/scopus-bio-preps-trials-of-gene-silencing-immuno-oncology-drug/
Preparing for the next decade of innovation in immuno-oncologyImmuno-oncology has seen some striking clinical advances in the 10 years since the approval of the first therapeutic Share XPreparing for the next decade of innovation in immuno-oncologyhttps://pharmaphorum.com/oncology/immuno-oncology-clinicial-trial-market-access/
Gilead trumpets data with newly-bought magrolimab in blood cancersJust three months after acquiring Forty Seven for $4.9 billion, Gilead has reported positive data on magrolimab, the Share XGilead trumpets data with newly-bought magrolimab in blood cancershttps://pharmaphorum.com/news/gilead-magrolimab-blood-cancer-asco/
AZ nabs a positive study for Imfinzi plus tremelimumab in liver cancerAfter a long run of trial disappointments, AstraZeneca is celebrating a win for its immuno-oncology combination of Imfinzi Share XAZ nabs a positive study for Imfinzi plus tremelimumab in liver cancerhttps://pharmaphorum.com/news/astrazeneca-imfinzi-tremelimumab-liver-cancer-asco-2020/
Roche signs up with Oncimmune to explore immunotherapy responsesRoche has doubled down on a partnership with UK biotech Oncimmune looking at how autoantibodies can affect patients’ Share XRoche signs up with Oncimmune to explore immunotherapy responseshttps://pharmaphorum.com/news/roche-signs-up-with-oncimmune-to-explore-immunotherapy-responses/
Merck & Co squares up to Roche with Keytruda data in triple-negative breast cancerRoche’s Tecentriq still has the market for front-line immunotherapy of triple-negative breast cancer (TNBC) to itself, but maybe Share XMerck & Co squares up to Roche with Keytruda data in triple-negative breast cancerhttps://pharmaphorum.com/news/mercks-squares-up-to-roche-with-keytruda-data-in-triple-negative-breast-cancer/
Merck builds case for six-week Keytruda dosing as FDA starts reviewMerck & Co’s checkpoint inhibitor Keytruda can be given half as often and still retain its efficacy, according Share XMerck builds case for six-week Keytruda dosing as FDA starts reviewhttps://pharmaphorum.com/news/merck-builds-case-for-six-week-keytruda-dosing-as-fda-starts-review/
Immuno-oncology latecomer GSK shows off PD-1 drug dataGlaxoSmithKline has new data showing that its cancer immunotherapy dostarlimab works as a second-line treatment for women with Share XImmuno-oncology latecomer GSK shows off PD-1 drug datahttps://pharmaphorum.com/news/immuno-oncology-latecomer-gsk-shows-off-pd-1-drug-data/
BMS gets an important win for Opdivo combination in kidney cancerBristol-Myers Squibb has staked another claim to the first-line kidney cancer market, with impressive new data for the Share XBMS gets an important win for Opdivo combination in kidney cancerhttps://pharmaphorum.com/news/bms-gets-an-important-win-for-opdivo-combination-in-kidney-cancer/
